Treatment of Dementia with Lewy Bodies and Parkinsonʼs Disease Dementia

Acid β-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α-synuclein processing

(2011) Valerie Cullen et al.   ANNALS OF NEUROLOGY

The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia

(2010) Victoria Larsson et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

(2010) Murat Emre et al.   LANCET NEUROLOGY

CSF  -synuclein as a diagnostic biomarker for Parkinson disease and related dementias

(2010) C. G. Ballard et al.   NEUROLOGY

Neurotoxic conversion of β-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

(2009) Masayo Fujita et al.   JOURNAL OF NEUROLOGY

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial

(2009) Dag Aarsland et al.   LANCET NEUROLOGY

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

(2009) Iracema Leroi et al.   MOVEMENT DISORDERS

Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems

(2008) Nicholas MacInnes et al.   JOURNAL OF NEURAL TRANSMISSION

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

(2008) P Edison et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY